Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

NCT05044039 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05044039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05044039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 28, 2022
Completion date
May 22, 2030
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, non-hodgkin lymphoma